3Q22 Investor Update

GVB ACCELERATES HEMP/CANNABIS REVENUE GROWTH Grow to positive cash flow and EBITDA from GVB operations Number of Participants Plant Profile / Roadmap Canna Metrix CannaMetrix's high- throughput proprietary, human cell-based assay technology serves as a roadmap for developing new plant lines with tailor-made profiles. Few Plant Biotechnology KeyGene Established proprietary bioinformatics platform and cutting-edge molecular breeding platform in partnership with KeyGene; capabilities include genetic engineering and plant line development Dozens (Few are advanced) Plant Breeding & Trials Extractas Bioscience Multiple partnerships with top global breeders provide 22nd Century with both northern and southern hemisphere, indoor and outdoor, year- round plant breeding and trial capabilities. Few Ingredient Extraction, Purification, and Finished Products GVB BIOPHARMA™ Hemp-derived active ingredients extractor and finished products manufacturer providing customers with bulk ingredients and white label products Dozens (Very few are reputable and with scale) Commercial Partners Ÿ 22nd Century offers an end-to-end, high-value add solution for leading nutraceutical, consumer products, and pharmaceutical companies entering the ascendant cannabis market. The addition of GVB positions 22nd Century as one of the largest, if not the largest, CBD suppliers to the North American merchant market. Thousands 22ND CENTURY GROUP 13

View entire presentation